Follicular Lymphoma News and Research

Latest Follicular Lymphoma News and Research

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, today announced that it has been selected by Verastem OncologyTM to dispense COPIKTRA (duvelisib) capsules.

28 Sep 2018

FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, today announced the U.S. Food and Drug Administration has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials.

24 Sep 2018

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Verastem, Inc., operating as Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced dosing of the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in combination with venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

6 Sep 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

New compounds targeting epigenetics show promise in lymphoma patients

New compounds targeting epigenetics have shown remarkable early activity in patients with lymphoma, according to data presented at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris, France.

5 Mar 2018

Study reveals HCT as effective treatment for NHL patients regardless of age

Results from a retrospective study of 1,629 patients with non-Hodgkin lymphoma showed that survival at 4 years following allogeneic hematopoietic cell transplantation for patients age 65 years and older is comparable to patients age 55 to 64 years.

21 Feb 2018

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients.

11 Dec 2017

VICC selected to administer FDA-approved CAR T therapy for treatment of lymphoma patients

Vanderbilt-Ingram Cancer Center has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR T) therapy for treatment of adult patients with a specific type of lymphoma.

25 Oct 2017

Dana-Farber, Brigham and Women's Cancer Center certified to offer new CAR T-cell therapy

Following a successful clinical trial involving Dana-Farber Cancer Institute and Brigham and Women's Hospital, the first chimeric antigen receptor (CAR) T-cell therapy for adult cancers was approved by the Food and Drug Administration today.

20 Oct 2017

FDA grants accelerated approval to new drug for treating relapsed follicular lymphoma

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies.

14 Sep 2017

Investigational compound for treating indolent lymphomas shows positive results in phase II clinical study

Bayer today announced positive data on its investigational compound copanlisib, an intravenous pan-Class I phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant inhibitory activity against PI3K-α and PI3K-δ isoforms.

31 Mar 2017

Study shows promising results for treating lymphoma patients with immune cell therapy

Lymphoma is the most common blood cancer. The disease occurs when immune cells called lymphocytes multiply uncontrollably. Cancerous lymphocytes can travel throughout the body and form lymph node tumors.

6 Jan 2017

New study reveals CAR T cells can function as micro-pharmacies for precise therapeutic delivery

There has been much recent excitement about immunotherapy and the use of genetically engineered chimeric antigen receptor (CAR) T cells.

30 Sep 2016

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixth leading cancer diagnosis in U.S. men and women, NHL has more than 30 sub-types, each featuring unique treatment choices and challenges.

30 Apr 2016

Autologous haematopoietic stem cell transplantation promise for myasthenia gravis

Study findings in seven patients with severe myasthenia gravis support the use of autologous haematopoietic stem cell transplantation for achieving long-term remission.

7 Apr 2016

Bacterium that causes Q fever associated with increased risk of lymphoma

The bacterium that causes Q fever, an infectious disease that humans contract from animals, is associated with an increased risk of lymphoma, according to a study published online today in Blood, the Journal of the American Society of Hematology.

13 Oct 2015

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas.

8 Sep 2015

Two years may be a more practical survival goal for patients with follicular lymphoma

The goal for many cancer patients is to reach the five-year, disease-free mark, but new research from UR Medicine's Wilmot Cancer Institute suggests that two years might be a more practical survival goal for people with follicular lymphoma.

30 Jun 2015

Non-invasive prenatal testing can detect maternal cancer at early stage

Non-invasive prenatal testing (NIPT) for chromosomal foetal disorders is used increasingly to test for conditions such as Down's syndrome. NIPT examines DNA from the foetus in the mother's blood, and therefore does not carry the risk of miscarriage involved in invasive testing methods.

7 Jun 2015

Follicular Lymphoma News and Research

Latest Follicular Lymphoma News and Research

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Celgene to share new and updated data around novel hematological therapies

New compounds targeting epigenetics show promise in lymphoma patients

Study reveals HCT as effective treatment for NHL patients regardless of age

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

VICC selected to administer FDA-approved CAR T therapy for treatment of lymphoma patients

Dana-Farber, Brigham and Women's Cancer Center certified to offer new CAR T-cell therapy

FDA grants accelerated approval to new drug for treating relapsed follicular lymphoma

Investigational compound for treating indolent lymphomas shows positive results in phase II clinical study

Study shows promising results for treating lymphoma patients with immune cell therapy

New study reveals CAR T cells can function as micro-pharmacies for precise therapeutic delivery

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

Autologous haematopoietic stem cell transplantation promise for myasthenia gravis

Bacterium that causes Q fever associated with increased risk of lymphoma

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Two years may be a more practical survival goal for patients with follicular lymphoma

Non-invasive prenatal testing can detect maternal cancer at early stage

Everything you should know about lymphoma eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Follicular Lymphoma News and Research

Latest Follicular Lymphoma News and Research

Everything you should know about lymphoma eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in